• Research Article
  • |
  • Open Access

Risk stratification in early stage arrhythmogenic cardiomyopathy and provocable brugada ECG

  • Stefan Peters
    • St. Elisabeth Hospital Salzgitter, Liebenhaller Str. 20, 38259 Salzgitter, Germany

  • Corresponding Author(s): Stefan Peters

  • St. Elisabeth Hospital Salzgitter, Liebenhaller Str. 20, 38259 Salzgitter, Germany

  • H.u.S.Peters@t-online.de

  • Peters S (2018).

  • This Article is distributed under the terms of Creative Commons Attribution 4.0 International License

Received : Aug 04, 2018
Accepted : Aug 27, 2018
Published Online : Aug 31, 2018
Journal : Annals of Cardiology and Vascular Medicine
Publisher : MedDocs Publishers LLC
Online edition : http://meddocsonline.org

Cite this article: Peters S. Risk stratification in early stage arrhythmogenic cardiomyopathy and provocable brugada ECG. Ann cardiol Vasc Med. 2018; 2: 1008.

Abstract

      Risk factors of malignant tachyarrythmias should be assessed in cases with early stage arrhythmogenic cardiomyopathy and provocable Brugada ECG. Spontaneous right precordial coved-type ST segment elevation, tall R wave in lead a VR, QRS fragmentation, 1° AV block, inducibility during electrophysiological examination, and localised right precordial QRS prolongation should be tested in 20 out of 128 patients.

      Only QRS fragmentation and localised right precordial QRS prolongation were positive in these patients. QRS fragmentation was positive in one patient, however without any arrhythmic events. Localised right precordial QRS prolongation was positive in five patients with serious arrhythmic events – four cases with previous ventricular fibrillation and one case with subsequent slow ventricular tachycardia. All other risk factors could be ruled out.

      In summary, localised right precordial QRS prolongation seems to be the strongest risk marker in cases of developing arrhythmogenic cardiomyopathy and provocable Brugada ECG.

Keywords: Arrhythmogenic cardiomyopathy; Brugada ECG; Localised right precordial QRS prolongation; QRS fragmentation; R-wave sign

Introduction

      The risk of aborted sudden cardiac death is very high in cases with developing arrhythmogenic cardiomyopathy and provocable Brugada ECG [1]. In about 10 - 15% of cases there seems to be an association between arrhythmogenic cardiomyopathy and Brugada syndrome by the so-called connexome – a linkage of desmosomal proteins, sodium channel complexes and gap junctions including desmosomal genes like plakophilin-2 [2], desmoglein-2 [3], desmoplakin [4], and plakoglobin (in animal models).

      Risk assessment in these cases is of utmost importance by spontaneous coved-type ST elevation in right precordial leads as the only independent risk marker [5], QRS fragmentation [6], positive R wave in lead a VR [7], 1° AV block [8], inducibility during electrophysiological examination [9], and as a new finding localized right precordial QRS prolongation demonstrated in the last ESC meeting in Barcelona 2017 [10] with a sensitivity of 78% and a specificity of 87%.

      Above mentioned risk factors were analysed in cases with possible or typical developing arrhythmogenic cardiomyopathy and provocable Brugada ECG.

Method

      In a cohort of 128 patients the diagnosis of typical (n=7, two major diagnostic criteria) and possible (n=13, one major and one minor diagnostic criteria) arrhythmogenic cardiomyopathy (72 males, meanage 46.1 +/- 13.6 years) was made. Diagnostic criteria were evaluated according to the paper published by Frank Marcus in 2010 [11]. Ajmaline challenge was used to provoke Brugada ECG that was positive in 20 cases (15%). In provoked Brugada ECG cases localised right precordial QRS prolongation, spontaneous Brugada ECG, tall R wave in lead a VR, 1° AV block, and inducibility during electrophysiological examination was analysed.

Results

      Localised right precordial QRS prolongation could be detected in 5 cases – four cases with aborted ventricular fibrillation before ICD implantation with the diagnosis of an early stage of arrhythmogenic cardiomyopathy and Brugada syndrome and one case of slow ventricular tachycardia 2 years after ICD implantation with the same diagnosis.

      In a single patient QRS fragmentation could be detected after ajmaline administration with the result of provocable Brugada ECG. This patient had no arrhythmice vents in a 72 months follow-up.

      Spontaneous coved-type ST elevation in right precordial leads, tall R wave in lead a VR, 1° AV block, and inducibility during electrophysiological examination could be excluded.

Discussion

      Since 2014 it is known that arrhythmogenic cardiomyopathy and Brugada syndrome have a common relationship in 10 – 15% of patients. The so-called connexome - an association between gap junctions, desmosomal proteins and sodium channel complexes – is the cause of this phenomenon and was first described in 2014 [1].

      In isolated Brugada syndrome without structural abnormalities some risk factors for the development of arrhythmic events have been described: A positive R wave in lead a VR [7], spontaneous coved-type ST elevation [5], QRS fragmentation [6], inducibility of tachyarrythmias during electrophysiological exanimation [9], and I° AV-block [8].

      In early stages of arrhythmogenic cardiomyopathy with provocable Brugada ECG the situation is different. Generally, the risk of ventricular fibrillation is extremely high, supporting the theory that Brugada syndrome is the main disease with developing arrhythmogenic cardiomyopathy [12].

      In the majority of patients (n=13) there was the diagnosis of possible arrhythmogenic cardiomyopathy without dilation and aneurysms of the right ventricle. In our group of patients there are no spontaneous cove-type ST-elevation in right precordial leads, no 1° AV block and during electrophysiological examination there were no inducibility of ventricular tachyarrhythmias in the cohort of 20 patients. In this group of patients a positive R wave of 3mm or more could be excluded; typical electrocardiographic appearance in lead a VR with significant Q wave, small R wave (2 mm or less), and negative T wave (2 mm or less) characterizes arrhythmogenic cardiomyopathy [13,14].

      QRS fragmentation after ajmaline administration was positive in a single case, however, without arrhythmic events in a 72 months’ follow-up.

      During a last ESC meeting in Barcelona 2017 another risk factor gained further importance: Localized right precordial QRS prolongation [10]. This risk factor was tested in more than 200 patients with a sensitivity of 78% and a specificity of 87%.

      In four patients (3 females) with aborted ventricular fibrillation before the diagnosis of arrhythmogenic cardiomyopathy was made and in one female patient with slow ventricular tachycardia after the diagnosis of arrhythmogenic cardiomyopathy with provocable Brugada ECG localized right precordial QRS prolongation was positive.

      In this small study sensitivity and specificity were both 100%, suggesting that localised right precordial QRS prolongation is a strongest predictor of previous and future arrhythmic events.

      Localized right precordial QRS prolongation is a strong diagnostic marker of arrhythmogenic cardiomyopathy [15] and - as it appears – the strongest risk factor in cases with developing arrhythmogenic cardiomyopathy and provocable Brugada ECG.

      The value of drug-induced type 1 Brugada ECG and cardiac arrest is controversely discussed: Newest register data reveal an increasing risk for cardiac arrest of about 50% [16].

      These results should be tested a larger collective of patients to gain statistically significant results. This aim is difficult to reach: Arrhythmogenic cardiomyopathy is a rare diagnosis and ajmaline testing in these patients is positive in only 15%.

References

  1. Cerrone M, Delmar M. Desmosomes and the sodium channel complex: implications for arrhythmogenic cardiomyopathy and Brugada syndrome. Trends Cardiovasc Med. 2014; 24: 184 – 90.
  2. Cerrone M, Lin X, Zhang M, Agullo-Pascual E, Pfenniger A, et al. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada Syndrome phenotype. Circulation. 2014; 129: 1092 – 103.
  3. DiResta C, Pietrelli A, Sala S, Della Bella P, DeBellis G, et al. Highthroughput characterization of a cohort of Brugada syndrome patients. Hum Nol Genet. 2015: 24: 5828 – 35.
  4. Zhao Q, Chen Y, Peng L, Gao R, Liu N, et al. Identification of rare variants of DSP gene in sudden unexplained nocturnal death syndrome in the southern Chinese Han population. Int J Legal Med. 2016; 130: 317 – 22.
  5. Rollin A, Sacher F, Gourrand JB, Pasquie JL, Raczka F, et al. Prevalence, characteristics, and prognosis role of type 1 ST elevation in the peripheral ECG leads in patients with Brugada syndrome. Heart Rhythm. 2013; 10: 1012 – 8.
  6. Meng L, Letsas KP, Baranchuk A, Shao Q, Tse G, et al. Metaanalysis of fragmented QRS as an electrocardiographic predictor for arrhythmic events in patients with Brugada syndrome. Front Physiol. 2017; 8: 678.
  7. Ragab AAY, Houck CA, van der Does LYME, Lanters EAH, Burghouwt DE, et al. Usefulness of the R-wave sign as a predictor for ventricular tachyarrhythmia in patients with Brugada syndrome. Am J Cardiol. 2017; 120: 428 – 34.
  8. Migliori F, Tesolina M, Zorzi A, Bertaglia E, Silvano M, et al. First-degree atrioventricular block on basal electrocardiogram predicts future arrhythmic events in patients with Brugada syndrome: A long-term follow-up study from the Veneto region of Northeastern Italy. Europace 2018.
  9. Takagi M, Sekiguchi Y, Yokoyama Y, Aihara N, Hiraka K. The prognostic impact on single extra-stimulus on programmed ventricular stimulation in Brugada patients without previous cardiac arrest: multi-centre study in Japan. Europace. 2017.
  10. Hunuk B, Mugnai G, De Asmundis C, Velagic V, Saitoh Y, et al. A novelrisk ECG feature in Brugada Syndrome probands: Localized QRS prolongation on right precordial leads. Eur Heart J. 2017; 38: 464.
  11. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/ dysplasia: Proposed modification of the Task Force Criteria. Eur Heart J. 2010; 31: 806-14.
  12. Peters S. Right precordial ST-Segment elevation in patients with arrhythmogenic cardiomyopathy and primary or secondary ventricular fibrillation. SJ Cardiovasc Dis. 2017; 2: 1008.
  13. Peters S. Clinical importance of lead a VR in arrhythmogenic cardiomyopathy. Int J Cardiol. 2014; 176: 508 – 9.
  14. Peters S. Low amplitude of inverted T-waves in lead a VR characterise patients with arrhythmogenic cardomyopathy. Int J Cardiol. 2016; 220: 201.
  15. Peters S, Trümmel M, Koehler B, Westermann KU. The value of different electrocardiographic depolarization criteria in the diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Electrocardiol. 2007; 40: 34 – 7.
  16. Delise P, Allocca G, Sitta N, Migliori F, Dagradi F, et al. Cardiac arrest and Brugada syndrome: Is drug-induced type 1 WCG pattern always a marker of low risk?. Int J Cardiol. 2017.

MedDocs Publishers

We always work towards offering the best to you. For any queries, please feel free to get in touch with us. Also you may post your valuable feedback after reading our journals, ebooks and after visiting our conferences.

CONTACT US